Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.44 |
| ▸ | TET3 | O43151 | 2/20 | 0.44 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL9719878 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL27302361 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL3061502 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL9719873 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL1533801 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL969854 | 0.98 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL969848 | 0.98 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL27560921 | 0.95 | SMN1; SMN2 (0.68) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL465928 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRTP53EGLN1EGLN3 | |
| Malic Acid SCHEMBL465926 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRTP53EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014020131-A1 | ANTIMICROBIAL COMPOSITION, DEVICE COMPRISING IT AND PROCESS | CRAWFORD HEALTHCARE LTD (GB) | 2014-02-06 | — | — | WO | claimed |
| WO-2014020133-A2 | PROCESS AND DEVICE | CRAWFORD HEALTHCARE LTD (GB) | 2014-02-06 | — | — | WO | claimed |
| EP-0850049-B1 | COMPOSITION FOR PH-DEPENDENT CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS FOR PRODUCING IT | POLYMER COREX KUOPIO LTD OY (FI) | 2002-06-26 | — | — | EP | claimed |
| EP-0850049-A1 | COMPOSITION FOR PH DEPENDENT CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS FOR PRODUCING IT | Oy Polymer Corex Kuopio Ltd. (FI) | 1998-07-01 | — | — | EP | claimed |
| WO-1997002018-A1 | COMPOSITION FOR PH DEPENDENT CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS FOR PRODUCING IT | OY POLYMER COREX KUOPIO LTD (FI) | 1997-01-23 | — | — | WO | claimed |
| EP-0228862-B1 | STABILIZED HUMAN TISSUE PLASMINOGEN ACTIVATOR COMPOSITIONS | GENENTECH, INC. (US) | 1992-08-12 | — | — | EP | claimed |
| US-4965357-A | CATIONIC TENSIDES, ANTIMETABOLITES | MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1990-10-23 | — | — | US | claimed |
| CN-116847831-A | Pharmaceutical composition of amorphous solid dispersion and preparation method thereof | 深圳市药欣生物科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11753323-B2 | In-situ remediation of sulfate contamination | COMMERCIAL LIABILITY PARTNERS, LLC (US) | 2023-09-12 | — | — | US | disclosed |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2022-05-17 | — | — | US | disclosed |
| US-20220033290-A1 | IN-SITU REMEDIATION OF SULFATE CONTAMINATION | COMMERCIAL LIABILITY PARTNERS, LLC | 2022-02-03 | — | — | US | disclosed |
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | ANTEIS SA (CH) | 2020-03-26 | — | — | US | disclosed |
| CN-105189531-B | Peptides for skin rejuvenation and methods of use thereof | 安特易斯有限公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-0236007-A1 | Process for the preparation of oxodisuccinates useful as detergent builders | THE PROCTER & GAMBLE COMPANY (US) | 1987-09-09 | — | — | EP | disclosed |
| US-4663278-A | Agglutination dependent enzyme channeling immunoassay | SYVA COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| US-4629690-A | COMPETITIVE PROTEIN BINDING USING A SECOND ENZYME RELATED TO THE FIRST BY THE PRODUCT OF ONE BEING THE SUBSTRATE OF THE OTHER | SYNTEX (U.S.A.) INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4423057-A | ANTISECRETORY, ANTICONVULSANT | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4374925-A | PROTEIN BINDING ASSAYS | SYVA COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4281061-A | DETECTABLE SIGNAL FROM FLUORESCENT DYE OR LABELED ENZYME | SYVA COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4275149-A | IMMUNOASSAY | SYVA COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TSHR 3828/4885TP53 1426/4885 |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | SMN1; SMN2 3195/4885TSHR 3828/4885TP53 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.